 VBL Therapeutics recently announced that they were allowed to add progression-free survival as a second primary endpoint for VB-111s Phase III OVAL study in ovarian cancer. The addition of the PFS endpoint could reduce VB-111s regulatory timeline by one year. Thus, moving VBL closer to commercialization. 